It really is an FDA-approved drug — but only for a specific population, and not for the visceral-fat and “growth-hormone optimization” uses you’re hearing about online. Here’s the honest difference, and the risks the marketing skips.
The one-sentence version: Tesamorelin is approved (as Egrifta) to reduce excess belly fat in people with HIV-associated lipodystrophy; everything else you’re hearing — visceral fat for the general population, body recomposition, anti-aging, “GH optimization” — is off-label, far less studied, and carries real IGF-1 and glucose considerations.
Tesamorelin is a synthetic analog of growth-hormone-releasing hormone (GHRH). Rather than being growth hormone itself, it signals the pituitary gland to release the body’s own growth hormone (GH) in a more natural, pulsatile pattern. The downstream effect of more GH is more IGF-1 (insulin-like growth factor 1), and one of the more consistent observed effects is a preferential reduction in visceral abdominal fat — the deep fat around the organs, as distinct from subcutaneous fat.
That visceral-fat effect is exactly why it was developed and approved for a specific problem — and also exactly why it has been seized on off-label.
This is the whole point of the guide, so it’s worth being precise.
| Use | Status | What the evidence supports |
|---|---|---|
| Excess visceral fat in HIV-associated lipodystrophy | FDA-approved | This is the indication tesamorelin was studied and approved for, with clinical trial data in that population. |
| Visceral fat in the general (non-HIV) population | Off-label | Mechanistically plausible and studied in some non-HIV metabolic contexts, but not an approved use; the risk/benefit in healthy adults is far less characterized. |
| “GH optimization,” anti-aging, body recomposition | Off-label / marketing | This is where community claims outrun the evidence. Benefits for healthy adults are not established, and the risks of chronically raising GH/IGF-1 are real. |
| Sleep, recovery, skin, “wellness” | Anecdotal | Community-reported, not demonstrated in controlled studies for these purposes. |
Why the distinction gets blurred: “It’s FDA-approved” is technically true and is used as a credibility shortcut by sellers and influencers — but approval is indication-specific. A drug approved to reduce a specific complication in people with HIV has not thereby been shown safe and effective for a healthy 40-year-old chasing a leaner midsection. Approval for one use is not a safety stamp for all uses.
In its approved population, tesamorelin produced meaningful reductions in visceral adipose tissue over the studied period, with effects that depended on continued treatment. This is the strongest part of the tesamorelin evidence base — and it is specific to that population and that problem.
The leap from “reduces visceral fat in HIV lipodystrophy” to “safe and effective for general fat loss, muscle, or longevity” is an extrapolation. It may turn out to help some people, but the controlled outcome data in healthy adults for these purposes is thin, and the long-term safety of chronically elevating GH/IGF-1 in people who don’t need it is not established.
Tesamorelin’s mechanism — raising GH and IGF-1 — is also the source of its most important risks. These are worth understanding before any off-label consideration.
If you have any history of a pituitary tumor (adenoma), do not use tesamorelin — or any growth-hormone secretagogue — without an endocrinologist. This is not hypothetical: people with a treated, stable adenoma do ask online whether they can add tesamorelin to a stack. The honest answer is that GH-axis stimulation is contraindicated in that situation and could risk tumor regrowth. That is a question for the endocrinologist managing the adenoma, never for a forum thread.
A common pattern right now: someone loses substantial weight on a GLP-1 (semaglutide, tirzepatide, retatrutide), notices stubborn visceral fat or worries about muscle/recomposition, and starts looking at tesamorelin to “target belly fat” or “optimize GH.” The logic is intuitive; the execution is where it gets risky.
The metabolic catch. GLP-1 receptor agonists tend to improve insulin sensitivity and glucose control. Tesamorelin, by raising growth hormone, tends to impair them. Running both means two potent agents pulling glucose metabolism in opposite directions — harder to monitor, easier to get wrong — layered on top of IGF-1 elevation and rapid weight loss. There is no clinical data on this combination. This is precisely the kind of stack that needs a clinician screening for contraindications and monitoring labs, not a social-media protocol.
When people say “tesamorelin,” they may mean one of two very different things:
This is the same affordability-driven gray market that surrounds GLP-1s and other peptides: a real, expensive approved option on one side, and a cheap, unverified channel on the other. If you are evaluating any gray-market peptide, third-party testing is the minimum baseline — see where to get peptides tested and how to evaluate a supplier.
Tesamorelin is the rare peptide in this space with a genuine FDA approval behind it — and that is exactly why it’s easy to overtrust. The approval is for reducing visceral fat in people with HIV-associated lipodystrophy. The off-label visceral-fat, body-composition, and “GH optimization” uses being promoted are a different, less-studied proposition, and the mechanism that makes tesamorelin work (more GH and IGF-1) is the same mechanism behind its most serious risks. None of that makes it “bad” — it makes it a real drug that deserves real medical oversight, screening, and monitoring, not a casually stacked add-on. If you’re considering it, that conversation belongs with a clinician who can check for contraindications (cancer history, glucose status) and monitor your labs.
Yes, but narrowly — as Egrifta, for reducing excess visceral abdominal fat in adults with HIV-associated lipodystrophy. That is its only approved indication. The visceral-fat, GH-optimization, and anti-aging uses discussed online are all off-label.
The approved drug (Egrifta) is legal with a prescription. Separately, “research” tesamorelin sold “for research use only” occupies the same unregulated gray zone as other research peptides — it is not the approved product and its contents are unverified.
Not established. The safety/efficacy data is from the HIV population, not healthy adults using it for body composition. It raises IGF-1 (a cancer-signaling concern; active malignancy is a contraindication) and growth hormone (which can worsen glucose control). Off-label use should involve clinician screening and monitoring.
This combination is uncharacterized and has a specific catch: GLP-1s tend to improve glucose control while tesamorelin tends to impair it, so they pull metabolism in opposite directions. Add IGF-1 elevation and there is real, unmonitored risk. There is no clinical data on the stack. Treat it as a clinician question, not a protocol to copy.
Generally yes — the visceral-fat effect depends on continued use and tends to reverse after discontinuation, similar to GLP-1 medications.
This guide is general legal and educational information, not legal or medical advice, and does not create an attorney-client or physician-patient relationship. It is written by a California-licensed attorney, not a physician. Discussion of off-label use is descriptive, not a recommendation. Tesamorelin (Egrifta) is a prescription drug; decisions about it — especially off-label or in combination with other medications — should be made with a licensed clinician who can screen for contraindications (including cancer history and glucose status) and monitor appropriate labs. Research peptides sold “for research use only” are not approved for human use. Verify current information before relying on it. Current as of June 20, 2026.